 DEVON, Pa., Aug. 09, 2021 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. Nasdaq: ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update. 